Get started
Novavax, Inc.Novavax, Inc.Novavax, Inc.

Novavax, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

NVAX chart


Full chart

Key facts today


Novavax's COVID-19 vaccine shows fewer symptoms than Pfizer-BioNTech's, with recipients reporting an average of 1.7 symptoms versus 2.8, and 24.2% experiencing grade 2 or higher symptoms.
A recent study, known as the Shield-Utah study, has shown that Novavax's COVID-19 vaccine induces lower reactogenicity symptoms compared to mRNA vaccines.
Analyze the impactAnalyze the impact

NVAX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.03 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.22 USD
Net income (FY)
‪−187.50 M‬ USD
Revenue (FY)
‪682.16 M‬ USD
Shares float
‪146.58 M‬
Beta (1Y)
1.75

Employees


Employees (FY)
952
Change (1Y)
−591 −38.30%
Revenue / Employee (1Y)
‪716.56 K‬ USD
Net income / Employee (1Y)
‪−196.95 K‬ USD

About Novavax, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
John C.s Jacobs
Website
novavax.com
Headquarters
Gaithersburg
Founded
1987
FIGI
BBG000NVSBL7
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NVAX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NVAX highest yielding bonds


NVAX5729297
Novavax, Inc. 5.0% 15-DEC-2027
Yield to maturity
9.44%
Maturity date
Dec 15, 2027

See all NVAX bonds 

Sparks


Curated watchlists where NVAX is featured.

See all sparks 


Check out other big names from the same industry as NVAX.

Frequently Asked Questions


The current price of NVAX is 6.39 USD — it has decreased by −0.31% in the past 24 hours. Watch Novavax, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Novavax, Inc. stocks are traded under the ticker NVAX.
NVAX stock has fallen by −6.03% compared to the previous week, the month change is a −23.01% fall, over the last year Novavax, Inc. has showed a 44.57% increase.
We've gathered analysts' opinions on Novavax, Inc. future price: according to them, NVAX price has a max estimate of 25.00 USD and a min estimate of 9.00 USD. Watch NVAX chart and read a more detailed Novavax, Inc. stock forecast: see what analysts think of Novavax, Inc. and suggest that you do with its stocks.
NVAX reached its all-time high on Feb 9, 2021 with the price of 331.68 USD, and its all-time low was 3.53 USD and was reached on Feb 5, 2024. View more price dynamics on NVAX chart.
See other stocks reaching their highest and lowest prices.
NVAX stock is 8.49% volatile and has beta coefficient of 1.75. Track Novavax, Inc. stock price on the chart and check out the list of the most volatile stocks — is Novavax, Inc. there?
Today Novavax, Inc. has the market capitalization of ‪1.03 B‬, it has increased by 9.00% over the last week.
Yes, you can track Novavax, Inc. financials in yearly and quarterly reports right on TradingView.
Novavax, Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
NVAX earnings for the last quarter are −0.51 USD per share, whereas the estimation was −0.51 USD resulting in a 0.78% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about Novavax, Inc. earnings.
Novavax, Inc. revenue for the last quarter amounts to ‪88.31 M‬ USD, despite the estimated figure of ‪84.38 M‬ USD. In the next quarter, revenue is expected to reach ‪71.77 M‬ USD.
NVAX net income for the last quarter is ‪−81.03 M‬ USD, while the quarter before that showed ‪−121.30 M‬ USD of net income which accounts for 33.20% change. Track more Novavax, Inc. financial stats to get the full picture.
No, NVAX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 952 employees. See our rating of the largest employees — is Novavax, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novavax, Inc. EBITDA is ‪−183.44 M‬ USD, and current EBITDA margin is −26.90%. See more stats in Novavax, Inc. financial statements.
Like other stocks, NVAX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novavax, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novavax, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novavax, Inc. stock shows the sell signal. See more of Novavax, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.